Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Abbott ID NOW Point-of-Care Testing

A legfontosabb adatok

Ki végzi
China Medical University Hospital
Hol
Tajvan1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
1080 fő, tervezett
Kezdés
2026. okt. 1.
Várható befejezés
2027. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Abbott ID NOW Point-of-Care Testing
  • Standard Laboratory-Based RT-PCR Diagnostic Pathway
A regiszteradat frissítve
2026. szeptember 29.

Ki vehet részt

Életkor
20 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 9 feltétel megnézéseKevesebb

Ki vehet részt

  • Acute onset of illness with fever (tympanic temperature ≥38°C) persisting for at least 24 hours
  • Acute onset of illness accompanied by decreased oxygen saturation (e.g., SpO₂ decreased to 94% or deterioration in oxygenation), or influenza infection highly suspected by the treating physician
  • Residents aged 65 years or older with comorbidities (e.g., diabetes mellitus, dialysis, hypertension, heart disease, or use of immunosuppressive agents) who develop acute illness with fever (tympanic temperature ≥37.5°C) persisting for at least 24 hours
  • At least one respiratory symptom, such as cough, sore throat, or rhinorrhea, persisting for at least 24 hours

Ki nem vehet részt

  • Participation in this study within the previous 14 days, to avoid duplicate enrollment for the same illness episode
  • A definite alternative diagnosis identified at the initial assessment that explains the influenza-like illness, such as bacterial pneumonia, non-respiratory infection, aspiration pneumonia following choking during feeding, definite urinary tract infection, or known exacerbation of heart failure without evidence of infection
  • Residence in a dedicated dementia care unit, because differences in disease characteristics, communication ability, and care practices may affect the internal validity of the study
  • Refusal by the resident or the resident's legally authorized representative to provide informed consent for data collection
  • Expected survival of less than 48 hours, as assessed by a physician

Ez a vizsgálat jelenleg itt érhető el: Tajvan.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

With the rapid aging of the global population, long-term care facilities (LTCFs) have become an increasingly important component of modern public health systems. However, these settings are also at high risk for outbreaks of respiratory infectious diseases. Influenza virus transmission within LTCFs has distinct epidemiological characteristics, including high transmissibility and high risks of severe illness and mortality. In Taiwan, with the accelerated aging of the population, LTCF residents commonly have multiple chronic comorbidities (multimorbidity) and age-related immune dysfunction (immunosenescence). Influenza infection in this population may not only lead to acute respiratory failure but may also contribute to a "silent burden," including post-infection cardiovascular events, metabolic dysregulation, and long-term functional decline.

A teljes eredeti leírásKevesebb

Under the current standard of care (SOC), influenza diagnosis relies on reverse transcription polymerase chain reaction (RT-PCR) testing performed by external laboratories, with a turnaround time (TAT) of approximately 24 to 48 hours. This time-to-result gap may delay clinical decision-making, potentially preventing timely initiation of antiviral treatment within the optimal 48-hour treatment window and leading facilities to adopt broad precautionary isolation measures, thereby increasing healthcare resource utilization and staffing burden.

The Abbott ID NOW system uses isothermal nucleic acid amplification technology (INAAT) and can provide molecular diagnostic results within approximately 15 minutes. Through a prospective cluster-randomized controlled design, this study aims to evaluate whether implementation of an ID NOW-based point-of-care testing (POCT) strategy can improve clinical outcomes among LTCF residents and reduce overall healthcare costs compared with the current standard diagnostic pathway.

A vizsgálat 2 csoportja

  • ID NOW Point-of-Care Testing StrategyA vizsgált kezelés

    Participants in this arm will receive point-of-care molecular testing for suspected influenza using the Abbott ID NOW system at the participating long-term care facility. Nasal or nasopharyngeal swab specimens will be collected on site, and the rapid test result will be used to support subsequent clinical management and infection prevention and control decisions.

    Kezelés: Abbott ID NOW Point-of-Care Testing

  • Standard Diagnostic PathwayMár használt kezelés, összehasonlításként

    Participants in this arm will receive the current standard diagnostic pathway for suspected influenza, including laboratory-based reverse transcription polymerase chain reaction (RT-PCR) testing performed through the usual external laboratory process, together with routine clinical management and infection-control measures.

    Kezelés: Standard Laboratory-Based RT-PCR Diagnostic Pathway

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluating the Clinical Outcomes of Abbott ID NOW Point-of-Care Testing for Respiratory Illnesses in Long-Term Care Facility Residents in Taiwan: Cluster-Randomized Controlled Trial
A regiszteradat frissítve
2026. szeptember 29.